Clinical Trial Update: Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating satraplatin in men with metastatic castration-resistant prostate cancer using a genomic signature for BRCAness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• satraplatin (satraplatin)

Snippet

Sponsor: William K. Oh | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-02-13